Investors seeking to outperform the market often focus on hand-picking stocks. Selecting the right ones has proven to be a key factor in boosting wealth.
After finishing at $75.27 in the prior trading day, Edwards Lifesciences Corp (NYSE: EW) closed at $76.25, up 1.30%. In other words, the price has increased by $1.30 from its previous closing price. On the day, 4.47 million shares were traded. EW stock price reached its highest trading level at $76.37 during the session, while it also had its lowest trading level at $75.39.
Ratios:
Our goal is to gain a better understanding of EW by taking a closer look at its different ratios. It provided that stocks Price–to–Cash (P/C) ratio for the trailing twelve months (TTM) is standing at 11.02 whereas its Price-to-Free Cash Flow (P/FCF) for the term is 76.15. For the most recent quarter (mrq), Quick Ratio is recorded 3.87 and its Current Ratio is at 4.68. In the meantime, Its Debt-to-Equity ratio is 0.07 whereas as Long-Term Debt/Eq ratio is at 0.06.
On April 24, 2025, Piper Sandler Upgraded its rating to Overweight which previously was Neutral but kept the price unchanged to $80.
Stifel Upgraded its Hold to Buy on January 30, 2025, whereas the target price for the stock was revised from $75 to $90.
Insider Transactions:
The insider trade also gives investors a glimpse into the future direction of stock prices, which can be beneficial to investors. A recent insider transaction in this stock occurred on Aug 25 ’25 when Chopra Daveen sold 2,500 shares for $81.95 per share. The transaction valued at 204,865 led to the insider holds 30,996 shares of the business.
Chopra Daveen bought 2,500 shares of EW for $204,865 on Aug 25 ’25. On Aug 18 ’25, another insider, Wood Larry L, who serves as the Global President TAVR & Surg of the company, sold 8,950 shares for $78.06 each. As a result, the insider received 698,679 and left with 206,900 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, EW now has a Market Capitalization of 44766375936 and an Enterprise Value of 41467973632. As of this moment, Edwards’s Price-to-Earnings (P/E) ratio for their current fiscal year is 52.05, and their Forward P/E ratio for the next fiscal year is 27.28. The expected Price-to-Earnings-to-Growth (PEG) calculation for the next 5 years is 5.75. For the stock, the TTM Price-to-Sale (P/S) ratio is 7.87 while its Price-to-Book (P/B) ratio in mrq is 4.25. Its current Enterprise Value per Revenue stands at 7.294 whereas that against EBITDA is 23.821.
Stock Price History:
The Beta on a monthly basis for EW is 1.05, which has changed by 0.15547812 over the last 52 weeks, in comparison to a change of 0.1529237 over the same period for the S&P500. Over the past 52 weeks, EW has reached a high of $83.00, while it has fallen to a 52-week low of $64.00. The 50-Day Moving Average of the stock is -2.74%, while the 200-Day Moving Average is calculated to be 2.01%.
Shares Statistics:
The stock has traded on average 4.38M shares per day over the past 3-months and 5361850 shares per day over the last 10 days, according to various share statistics. A total of 587.90M shares are outstanding, with a floating share count of 575.05M. Insiders hold about 2.05% of the company’s shares, while institutions hold 86.91% stake in the company. Shares short for EW as of 1757894400 were 7260305 with a Short Ratio of 1.66, compared to 1755216000 on 8138216. Therefore, it implies a Short% of Shares Outstanding of 7260305 and a Short% of Float of 1.39999995.
Earnings Estimates
Edwards Lifesciences Corp (EW) is currently under the scrutiny of 26.0 analysts, each contributing to the ongoing evaluation of its stock.The consensus estimate for the next quarter is $0.61, with high estimates of $0.7 and low estimates of $0.56.
Analysts are recommending an EPS of between $2.55 and $2.48 for the fiscal current year, implying an average EPS of $2.51. EPS for the following year is $2.79, with 31.0 analysts recommending between $2.93 and $2.66.
Revenue Estimates
27 analysts predict $1.49B in revenue for . The current quarter. It ranges from a high estimate of $1.52B to a low estimate of $1.46B. As of . The current estimate, Edwards Lifesciences Corp’s year-ago sales were $1.35BFor the next quarter, 27 analysts are estimating revenue of $1.54B. There is a high estimate of $1.6B for the next quarter, whereas the lowest estimate is $1.52B.
A total of 32 analysts have provided revenue estimates for EW’s current fiscal year. The highest revenue estimate was $6.01B, while the lowest revenue estimate was $5.81B, resulting in an average revenue estimate of $5.97B. In the same quarter a year ago, actual revenue was $5.44BBased on 31 analysts’ estimates, the company’s revenue will be $6.54B in the next fiscal year. The high estimate is $6.73B and the low estimate is $6.28B.
